Filing Flows › Health Care › Wave Life Sciences (WVE)
Wave Life Sciences (WVE) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Oct 27, 2026 · Wave Life Sciences (WVE) Q3 2026 earnings results →
Q3 2026 Revenue up 73% year over year to $13.2M · 471¢ of every $1 of revenue lost · operating margin -502.0%
Wave Life Sciences made $13.2M in Q3 2026 (+73% Y/Y). Operating margin -502.0%, net loss $61.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Oct 27, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $13.2M in Q3 2026, up 73% year over year and up 479% from the previous quarter.
Operating costs exceeded revenue by $66.0M, an operating margin of -502.0%. Total costs grew 24% against revenue growth of 73%. The fastest-growing cost line was General & admin (+40%). The quarter ended with a net loss of $61.9M, narrower than the previous quarter's $69.4M loss.
Operating cash flow was −$60.1M. Non-cash charges added back $880K of depreciation and $10.3M of share-based compensation. Working capital and other items used $9.4M. Capital expenditures of $15K exceeded it, leaving free cash flow of −$60.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Oct 27, 2026 | $13.2M | +73% | -502.0% | −$61.9M | −$60.1M |
| Q2 2026 | 10-Q | Jul 30, 2026 | $2.3M | -74% | n/m | −$69.4M | −$53.6M |
| Q1 2026 | 10-Q | Apr 28, 2026 | $38.2M | +317% | -81.8% | −$26.1M | −$59.6M |
| Q2 2025 | 10-Q | Jul 30, 2025 | $8.7M | -56% | -606.5% | −$50.5M | −$46.0M |
| Q1 2025 | 10-Q | May 8, 2025 | $9.2M | -27% | -542.8% | −$46.9M | −$63.0M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Wave Life Sciences
We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid (“RNA”) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM ® , combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides us with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology.
In its own words, from its 10-K, filed Feb 26, 2026.
Wave Life Sciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +73% against the peers' median +10%. Operating margin: -502.0% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| WVE Wave Life Sciences | Q3 2026 | $13.2M | +73% | -502.0% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Wave Life Sciences 10-Q on SEC EDGAR · CIK 1631574 · Pharmaceutical Preparations
13F: who owns WVE and who is buying
More on WVE
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q2 2025 results · Q1 2025 results